[P3–038]: ANTI‐AMYLOID ANTIBODIES AS A POTENTIAL THERAPEUTIC FOR ALZHEIMER's DISEASE: NEUROPROTECTIVE ACTIVITY OF SAR228810 AGAINST AMYLOID‐INDUCED NEUROTOXICITY IN VITRO

Taupin, Véronique; Vaucher, Nadine; Loux, Christophe; Parc, Josiane Le; Michoux, François; Colonna, Christine; Capdevila, Cécile; Ferrari, Paul; Jeannin, Pascale; Cohen, Caroline; Pradier, Laurent; Bertrand, Philìppe

doi:10.1016/j.jalz.2017.06.1851

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It binds specifically to soluble protofibrillar and fibrillar forms of Aβ and it is relatively inactive against Aβ monomers and small oligomeric aggregates (130). Co-application of SAR228810 and oligomeric Aβ 42 preparations significantly inhibited Aβ-induced neurotoxicity in primary neurons (131). Preclinical pharmacological studies of SAR255952 in APPSL mice showed that a chronic 4-month treatment dose-dependently prevented brain amyloid plaque formation.…”

Section: Sar228810mentioning

confidence: 99%

Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease

Zampar

Wirths

2020

Alzheimer’s Disease: Drug Discovery

View full text Add to dashboard Cite

Neurodegenerative diseases, in particular Alzheimer' s disease, represent significant unmet medical needs due to a lack of effective therapeutic treatment options and cause a substantial burden for health care systems. Accumulation of β-amyloid peptides within the brain is believed to be an initial trigger of the disease process. In the last 20 years, immunotherapy has emerged as a promising target-directed strategy to develop efficient treatment options with disease-modifying potential. Unfortunately, either active vaccination against β-amyloid or its fragments, as well as passive immunization using monoclonal antibodies, have largely failed to show a clinical benefit in a variety of clinical trials. This chapter addresses progress and developments with regard to active and passive immunization against Aβ and summarizes the current state of clinical trials.

show abstract

Section: Sar228810mentioning

confidence: 99%